Novistra Capital
Top Layer Top Layer
healthcare-2560x515

Healthcare

Linkedin Icon X Icon

Novistra Capital advises IDD Biotech on its license agreement with Enzene Biosciences, a subsidiary of Alkem Labs

Novistra Capital, a New York based boutique advisory, announced today that International Drug Development Biotech (IDD Biotech) a Lyon, France based biotech company, has entered into an exclusive license agreement with Enzene Biosciences, subsidiary of Alkem Laboratories Limited.

Under this agreement, Enzene will be granted an exclusive license for manufacturing clinical batches of IDD’s CD 19 product for Phase 1, 2 and 3 clinical trials at its c-GMP compliant manufacturing plant in India. IDD’s anti-CD19 product has the potential to be the “Best-in-class” therapeutic alternative to anti-CD20 MAbs (Monoclonal Antibodies) in failing (refractory, resistant, relapse or association) cases. Enzene’s “Continuous Manufacturing Platform” and fully automated continuous c-GMP compliant manufacturing plant for MAbs production is complementary to IDD’s R&D capabilities.

IDD Biotech, established in 2008, has developed a strong portfolio of MAbs focused on Oncology/ Hematology indications over the last 10 years. During this period, many of IDD’s products have been licensed to global biotech and pharmaceutical companies. Enzene, an innovation driven, fast growing company, based in Pune, India, has developed multiple novel and advanced technological platforms with an aim to disrupt the affordability of biotech products globally.

healthcare-2560x515

Deal Team

Pankaj-1-2560x2560

Pankaj Arora

Managing Director

Subscribe to Novistra Insights

Latest news and insights delivered directly to your inbox.

By subscribing you agree to with our Privacy Policy.

By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.

bg-2560x1977

From the Newsroom

View All
Rectangle-426-1-scaled-2560x718

Ideas are better
explored together

To read more, download report

Latest news and insights delivered directly to your inbox.

Report is delivered in your inbox.

By subscribing you agree to with our Privacy Policy.